Key result
Systematic registry-based evaluation clarifies real-world value by distinguishing cost-effective CV therapies from ineffective ones.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Redfors et al. (2022) studied this question. Systematic registry-based evaluation expands the evidence base of new cardiovascular treatments by helping distinguish cost-effective, life-saving therapies from costly, ineffective ones.
Synapse has enriched 10 related papers. Consider them for comparative context: